BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cenduit, LLC Release: Free Webinar Explores Blinding Strategies Using IRT Systems


3/19/2013 11:44:52 AM

(Durham, N.C.; March 19, 2013) — Implementing the optimum strategy for patient randomization and drug management though the use of interactive response technology can greatly reduce waste and improve efficiency in blinded clinical trials. However, IRT can increase the risks of partial unblinding unless those risks are minimized through careful design of the drug supply/resupply and patient/drug assignment aspects of the system.

In a new, on-demand webinar, Stefan Duerr, associate director of project management at Cenduit LLC, describes ways unblinding can occur during a study and warns that even partial unblinding can seriously compromise data.

Titled “Avoid Unblinding Risks when Defining Drug Supply Strategy in an IRT System,” the webinar points out that investigators or other site staff often unwittingly obtain information that enables them to guess the treatment of a patient with higher probability than if based on chance alone.

“The difficulty is that an investigator with some unblinding clues may, consciously or unconsciously, begin to look for corroborating evidence, and over time the accuracy of his or her guesses improve,” Duerr said.

Duerr’s recommendations in the webinar include taking steps to ensure that communications reach their intended audience and making certain that the treatment group list and the medication list are kept separate and randomly assigned.

“Particularly when drugs are being resupplied to a site or supplied in response to a specific event, dispensing based on the same sequence as the kit list can easily give investigators clues that can potentially lead to biased behavior,” Duerr said.

The webinar is free and can be viewed at any time by clicking this link or by visiting the Cenduit website at www.cenduit.com.

About Cenduit LLC

Cenduit provides interactive response technology (IRT) - driven services for clinical trials around the world. Cenduit’s IRT solutions deliver optimized clinical supply chain management and facilitate precise control over patient randomization and drug administration to enable more efficient, compliant trials. With expert personnel located around the globe, Cenduit’s unprecedented level of support currently covers more than 16,000 sites in more than 100 countries. Focus on trials, not tribulations, with Cenduit. For more information or to connect with Cenduit, visit www.cenduit.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES